NCT03624504CompletedNot Applicable
China Micra Transcatheter Pacing Study
Medtronic Cardiac Rhythm and Heart Failure7 sites in 1 country82 target enrollmentStarted: July 31, 2018Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 82
- Locations
- 7
- Primary Endpoint
- Percentage of Participants With Major Complications Free Survival Probability
Study Overview
Brief Summary
The China Micra Transcatheter Pacing Study is a prospective, multi-center, single arm human clinical trial utilizing Objective Performance Criterion (OPC) to confirm the safety and efficacy profile of the Micra system for regulatory approval in China.
Detailed Description
All study sites will be in China. Subjects successfully implanted with the Micra system in all sites will be followed at implant/pre-discharge, 1-month, 3-months, and 6-months, and at 6-month intervals thereafter (if applicable) through study closure. The overall follow-up period of the study will end when the last enrolled patient has 6 months of follow-up.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subjects who have a Class I or II indication for implantation of a single chamber ventricular pacemaker according to ACC/AHA/HRS 2008 guidelines and China guideline.
- •Subjects who are willing to participate in study through consent and willing to undergo study specific required procedures with expectancy of geographically stable for follow up duration.
- •Subjects who are at least 18 years of age.
Exclusion Criteria
- •Subject has an existing or prior pacemaker, ICD or CRT device implant.
- •Subject has unstable angina pectoris or has had an acute myocardial infarction (AMI) in the 30 days prior to eligibility assessment.
- •Subjects with current implantation of neurostimulator or any other chronically implanted device which uses current in the body. Note that a temporary pacing wire is allowed.
- •Subjects with a mechanical tricuspid valve, implanted vena cava filter, or left ventricular assist device (LVAD).
- •Subjects who are morbidly obese and physician believes telemetry communication of ≤5 inches (12.5 cm) could not be obtained with programmer head.
- •Subjects whose femoral venous anatomy is unable to accommodate a 23 French introducer sheath or implant on the right side of the heart (for example, due to obstructions or severe tortuosity) in the opinion of the implanter.
- •Subjects who are considered as unable to tolerate an urgent sternotomy.
- •Subjects with a known intolerance to Nickel-Titanium (Nitinol) Alloy.
- •Subjects for whom a single dose of 1.0mg dexamethasone acetate may be contraindicated.
- •Subjects with a life expectancy of less than 12-months.
- •Subjects who are currently enrolled or planning to participate in a potentially confounding drug or device trial during the course of this study. Co-enrollment in concurrent trials is only allowed when document pre-approval is obtained from the Medtronic study manager.
- •Pregnant women or breastfeeding women, or women of child bearing potential and who are not on a reliable form of birth regulation method or abstinence.
- •Subjects with exclusion criteria required by local law (age or other).
- •Subjects with medical condition which precludes patient from participation in the opinion of the Investigator.
Outcomes
Primary Outcomes
Percentage of Participants With Major Complications Free Survival Probability
Time Frame: 6 months post implant
Freedom rate from Micra implant procedure and/or system related major complications through 6 months post implant
Secondary Outcomes
- Adverse Device Effect(From implant attempt to last subject follow-up, ranging from 0 to 14 months)
- Pacing Capture Threshold (PCT)(Implant, Discharge, Month 1, Month 3, Month 6)
- Impedance(Implant, Discharge, Month 1, Month 3, Month 6)
- Sensing Amplitude(Implant, Discharge, Month 1, Month 3, Month 6)
Investigators
Study Sites (7)
Loading locations...
Similar Trials
Completed
Not Applicable
Micra Transcatheter Pacing StudyClass I or II Indication for Implantation of a Single Chamber Ventricular Pacemaker According to ACC/AHA/HRS 2001 Guidelines and Any National GuidelinesNCT02004873Medtronic Cardiac Rhythm and Heart Failure744
Completed
Not Applicable
MICRA Transcatheter Pacing Studybradycardiaslow heart rate10007521NL-OMON38829Medtronic Trading NL BV30
Not yet recruiting
Phase 2
Micra Study - to evaluate the safety and effectiveness of the Micra pacemaker and to assess its long-term performance.CTRI/2015/01/005445India Medtronic Pvt Ltd780
Enrolling By Invitation
Not Applicable
Safety and Efficacy of SinocrownTM Transcatheter Aortic Valve Replacement SystemTranscatheter Aortic Valve ReplacementNCT05202977Lepu Medical Technology (Beijing) Co., Ltd.10
Completed
Phase 3
PaTHway CHINA TRIAL: A Trial to Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With HypoparathyroidismParathyroid Hormone DeficiencyEndocrine System DiseasesParathyroid DiseasesHypoparathyroidismNCT05387070Visen Pharmaceuticals (Shanghai) Co., Ltd.81